BridgeMD
New treatment option for Immunosenescence
Official title The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.
ClinicalTrials.gov ID: NCT06907329
What this study is testing
- What it's testing
- The ageing of our country is increasing and the ageing of the population has led to a significant increase in aging related diseases. During the aging process of the organism, cellular senescence can occur in all systems of the body, of which the senescence of the immune system is called immunosenescence.
- Time commitment: about 26 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 70
You may be able to join if
- Age 50-70 years with overweight or obesity (BMI 24kg/m2);
- At least one of the following three: metabolism-related fatty liver disease (diagnosed by ultrasound); pre-diabetes; type 2 diabetes mellitus with...
- Agreed to participate in the trial and could adhere to the follow-up and visit the hospital on their own; signed the informed consent form.
You likely can't join if
- Patients with tumours;
- Patients with autoimmune diseases (excluding Hashimoto's thyroiditis);
- Severe cardiovascular disease or cardiac insufficiency;
- Systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg;
- Chronic obstructive pulmonary disease;
- Chronic active hepatitis or cirrhosis;
See the full eligibility criteria
- Age 50-70 years with overweight or obesity (BMI 24kg/m2);
- At least one of the following three: metabolism-related fatty liver disease (diagnosed by ultrasound); pre-diabetes; type 2 diabetes mellitus with HbA1c \<7% without glucose-lowering drug therapy;
- Agreed to participate in the trial and could adhere to the follow-up and visit the hospital on their own; signed the informed consent form.
- Patients with tumours;
- Patients with autoimmune diseases (excluding Hashimoto's thyroiditis);
- Severe cardiovascular disease or cardiac insufficiency;
- Systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg;
- Chronic obstructive pulmonary disease;
- Chronic active hepatitis or cirrhosis;
- Chronic renal insufficiency;
- Stroke patients
- Severe haematological diseases;
- Infectious diseases;
- Mental illness;
- Other conditions that, in the opinion of the investigator, may affect the results of the study;
- Those who have used NMN or other anti-aging agents within six months.
- Premenopausal woman
- ALT, AST values are more than three times higher than the upper limit of the normal reference range
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 26 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.